林爱兰，2020年12月博士毕业于福州大学生物化工专业，2021年3月至2023年3月在中国科学院杭州医学研究所谭蔚泓院士课题组从事博士后。研究方向包括基于aptamer核酸偶联药物的设计与开发，临床样本来源的肿瘤模型的构建。2023年5月加入西湖大学基因组学与生物信息学核心实验室，担任助理研究员，主要从事基于mRNA/LNP技术构建体内CAR-T用于肿瘤等相关疾病的治疗研究。

        Dr. Ailan Lin is majoring in Biochemistry and graduated from Fuzhou University in December 2020. She worked as a postdoctoral fellow in the group of Professor Weihong Tan at the Hangzhou Institute of Medical Research, Chinese Academy of Sciences, from March 2021 to March 2023. Dr. Lin's research interests include designing and developing APtamER-based nucleic acid-coupled drugs and constructing mouse tumor models in which tumor cells are derived from clinical patients. In May 2023, Dr. Lin joined the Genomics and Bioinformatics Core Lab. of Westlake Laboratory at Westlake University. As an assistant research fellow, she mainly engaged in the research of constructing in vivo CAR-T based on LNP embedding mRNA technology for the treatment of tumors and other related diseases.